Nemluvio is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives itch and is involved in inflammation and skin barrier ...
FE Investments (FEI) has selected technology vendor Jacobi Strategies (Jacobi) to enhance the discretionary fund manager's model portfolio capabilities. Jacobi's institutional-grade investment ...
We are maintaining our $59 per share fair value estimate for Kilroy Realty after incorporating fourth-quarter results. Our estimate of Kilroy’s long-term weighted average cost of capital is 7.1%, and ...
When you search International Day of Women and Girls in Science, the knowledge panel on Google calls it a "celebration" of women in STEM, but in 2025 it's far from a jubilant affair. A concerted push ...
As a result, Healthpeak’s life science and medical office portfolios are now prominently featured in the company's portfolio as the proceeds from the senior housing sales were reinvested into these ...